https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27649 Wed 17 May 2017 11:47:32 AEST ]]> Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20455 Wed 11 Apr 2018 16:49:10 AEST ]]> MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15166 V600E melanoma cells to B-RAF inhibitors. Experimental Design: B-RAFV600E melanoma cells were exposed to the B-RAF inhibitor PLX4720 for prolonged periods to select for cells resistant to apoptosis induced by the inhibitor. The resultant cells were analyzed for activation of extracellular signal regulated kinase (ERK), MAP/ERK kinase (MEK), and Akt, and related signals. Their roles in survival of the cells were also examined. Results: B-RAFV600E melanoma cells selected for resistant to PLX4720-induced apoptosis retained the V600E mutation in B-RAF, and proliferated steadily in the presence of the inhibitor, albeit with slow growth rate. These cells displayed high levels of ERK activation, that is, at least in part, independent of the conventional RAF/MEK/ERK pathway, as MEK activation was low and inhibition of MEK did not significantly block activation of ERK. In contrast, extracellular signals appeared involved. This was associated with elevated activation of the phosphoinositide 3-kinase (PI3k)/Akt pathway and could be inhibited by serum starvation and inhibition of PI3k/Akt. Inhibition of MEK did not impact on survival of these cells, whereas serum starvation, inhibition of PI3K/Akt, and inhibition of ERK1/2 reduced their viability. Conclusions: These results indicate that sensitivity to induction of apoptosis may be a major determinant of long-term responses of B-RAFV600E melanomas to specific inhibitors and suggest that rebound melanoma growth after initial treatment with the inhibitors may not be responsive to MEK inhibitors, but may be susceptible to inhibition of the PI3k/Akt pathway.]]> Wed 11 Apr 2018 16:15:39 AEST ]]> Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14866 Wed 11 Apr 2018 16:08:27 AEST ]]> Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15167 Wed 11 Apr 2018 16:01:18 AEST ]]> Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14356 Wed 11 Apr 2018 15:41:30 AEST ]]> MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13811 Wed 11 Apr 2018 15:41:21 AEST ]]> 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6913 Wed 11 Apr 2018 15:38:21 AEST ]]> Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28543 Wed 11 Apr 2018 15:37:28 AEST ]]> Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14865 Wed 11 Apr 2018 14:49:29 AEST ]]> OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14361 Wed 11 Apr 2018 13:27:51 AEST ]]> Metabolic approaches to treatment of melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6915 Wed 11 Apr 2018 13:15:26 AEST ]]> Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1002 Wed 11 Apr 2018 12:48:56 AEST ]]> PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14353 Wed 11 Apr 2018 11:50:58 AEST ]]> P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13895 Wed 11 Apr 2018 11:47:28 AEST ]]> Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:219 Wed 11 Apr 2018 11:20:13 AEST ]]> Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9196 Wed 11 Apr 2018 10:54:31 AEST ]]> Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5046 Wed 11 Apr 2018 10:25:08 AEST ]]> Treatment combinations targeting apoptosis to improve immunotherapy of melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6917 Wed 11 Apr 2018 09:56:34 AEST ]]> A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9730 8 and ≤ 10 g/dL and ≤ 8 g/dL was more common in the bosentan group. Conclusions: In patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters. There were no unexpected safety findings. Trial registration: This study is registered in ClinicalTrials.gov under the unique identifier NCT01009177.]]> Wed 11 Apr 2018 09:56:16 AEST ]]> Somatic copy number amplification and hyperactivating somatic mutations of EZH2 correlate with DNA methylation and drive epigenetic silencing of genes involved in tumor suppression and immune responses in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29412 Wed 11 Apr 2018 09:50:06 AEST ]]> Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5430 Wed 11 Apr 2018 09:25:36 AEST ]]> Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34826 Thu 13 Jan 2022 10:31:11 AEDT ]]> Current strategies in overcoming resistance of cancer cells to apaptosis melanoma as a model https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3484 Sat 24 Mar 2018 10:57:58 AEDT ]]> Current strategies in overcoming resistance of cancer cells to apaptosis melanoma as a model https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3483 Sat 24 Mar 2018 10:57:58 AEDT ]]> Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7349 Sat 24 Mar 2018 08:40:16 AEDT ]]> Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7006 Sat 24 Mar 2018 08:37:51 AEDT ]]> Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7007 Sat 24 Mar 2018 08:37:51 AEDT ]]> Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7958 Sat 24 Mar 2018 08:34:56 AEDT ]]> Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6918 Sat 24 Mar 2018 08:34:50 AEDT ]]> Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6919 1.0 mm) primary melanoma. It was 18 and 17.3 in subcutaneous and lymph node metastases, respectively (P < 0.0001). GRP78 expression was positively correlated with increasing tumour thickness (P = 0.001) and with increasing dermal tumour mitotic index (P = 0.0004). Disease-free survival (χ² = 8.0703, P = 0.0045) and overall survival (χ² = 6.2633, P = 0.0123) in melanoma patients with IRS >25 were significantly lower than in melanoma patients with IRS <25. Conclusions: GRP78 expression appears to correlate with known correlates of melanoma progression and survival and requires further evaluation as a prognostic biomarker in melanoma.]]> Sat 24 Mar 2018 08:34:50 AEDT ]]> Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1946 Sat 24 Mar 2018 08:33:19 AEDT ]]> Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:999 Sat 24 Mar 2018 08:29:51 AEDT ]]> Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:995 Sat 24 Mar 2018 08:29:49 AEDT ]]> Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor–related apoptosis-inducing ligand https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1240 Sat 24 Mar 2018 08:28:31 AEDT ]]> The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15221 Sat 24 Mar 2018 08:26:08 AEDT ]]> Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10937 1.0mm) (95%) and in metastatic melanoma in the skin (100%) and lymph node (81%). The immunoreactive score was highly related to progression of melanoma (P<0.0001). LDH5 expression was positively associated with increasing tumor thickness (P=0.02) and dermal tumor mitotic rate (P=0.02). LDH-5 above the median immunoreactive score was associated with reduced disease-free survival and overall survival (P<0.02). LDH-5 expression was negatively associated with Bcl-2 expression. In contrast, LDH-5 expression was strongly associated with Bcl-XL and Mcl-1 expression and also positively associated with GRP78 expression (P<0.0001). The low Bcl-2 expression in melanomas with high LDH-5 expression provides an explanation for the poor response of patients with high serum LDH levels to treatment with the Bcl-2 antisense drug ‘Genasense’. The strong correlation of LDH-5 expression with Mcl-1 expression suggests that treatment strategies inhibiting the activity of Mcl-1 in melanoma patients should be investigated.]]> Sat 24 Mar 2018 08:13:21 AEDT ]]> Nucleotide excision repair gene expression after cisplatin treatment in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11525 Sat 24 Mar 2018 08:10:22 AEDT ]]> Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11117 20 months; 5 (63%) remained alive. Clinical benefit rate (overall response + stable disease) was 21% (16 partial responses and 35 stable disease), and median overall survival was 10.0 months. Progression-free survival at 6 months was 15%, and survival was 40.3% at 12 months and 22% at 24 months. Common treatment-related adverse events were generally mild to moderate, and grade 3/4 adverse events included diarrhea (n = 28, 11%), fatigue (n = 6, 2%), and colitis (n = 9, 4%). There were 2 (0.8%) treatment-related deaths. Conclusions: Tremelimumab showed an objective response rate of 6.6%, with all responses being durable ≥170 days since enrollment, suggesting a potential role for tremelimumab in melanoma.]]> Sat 24 Mar 2018 08:09:51 AEDT ]]> Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10716 Sat 24 Mar 2018 08:08:26 AEDT ]]> Contrasting effects of Nutlin-3 on TRAIL- and Docetaxel-induced Apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10447 Sat 24 Mar 2018 08:08:03 AEDT ]]> Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20093 Sat 24 Mar 2018 08:00:06 AEDT ]]> Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20878 Sat 24 Mar 2018 07:57:56 AEDT ]]> Side effects and toxicities of targeted therapies in stage IV melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20976 Sat 24 Mar 2018 07:54:20 AEDT ]]> The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20163 Sat 24 Mar 2018 07:51:41 AEDT ]]> Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5563 Sat 24 Mar 2018 07:49:11 AEDT ]]> Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5683 Sat 24 Mar 2018 07:47:32 AEDT ]]> Overcoming resistance to apoptosis in cancer therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6686 Sat 24 Mar 2018 07:46:12 AEDT ]]> Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5319 Sat 24 Mar 2018 07:45:57 AEDT ]]> Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5341 Sat 24 Mar 2018 07:45:56 AEDT ]]> Involvement of endoplasmic reticulum stress in docetaxel-induced JNK-dependent apoptosis of human melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5394 Sat 24 Mar 2018 07:43:57 AEDT ]]> Melanoma cell sensitivity to docetaxal-induced apoptosis is determined by class III β-tubulin levels https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5398 Sat 24 Mar 2018 07:43:56 AEDT ]]> Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29413 Sat 24 Mar 2018 07:36:21 AEDT ]]> Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29414 Sat 24 Mar 2018 07:36:12 AEDT ]]> Targeting apoptotic pathways in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25800 Sat 24 Mar 2018 07:34:44 AEDT ]]> EZH2 as a mediator of treatment resistance in melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29370 Sat 24 Mar 2018 07:34:17 AEDT ]]> Association of pembrolizumab with tumor response and survival among patients with advanced melanoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29369 Sat 24 Mar 2018 07:34:17 AEDT ]]> Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3411 Sat 24 Mar 2018 07:21:36 AEDT ]]> Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22175 Sat 24 Mar 2018 07:14:58 AEDT ]]> The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23422 Sat 24 Mar 2018 07:13:54 AEDT ]]> Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48634 3.5-fold after steroid and ATG treatment. This case illustrates the need to consider this form of steroid resistance in patients failing treatment with corticosteroids. It also highlights the need for both better identification of patients at risk and the development of treatments that involve more specific immune suppression.]]> Mon 03 Apr 2023 10:14:28 AEST ]]>